How labs verify semaglutide in the pen

When a batch of semaglutide is released from a manufacturing facility, regulators and quality-control teams need to know two things: that the product contains the stated amount of active substance, and that it is free from degradants that could change potency or safety. A 2026 review in the Journal of Chromatography B by Kavibharathi, Thirusha, Vijayadevan, Vijayakumar, and Nalini surveyed every published analytical approach for making those two determinations.^[1]

The review covers semaglutide in two distinct settings: pharmaceutical formulations (the pen-injector and tablet presentations that clinicians prescribe) and biological matrices (principally human plasma, where pharmacokinetic studies measure the drug as it moves through the body after dosing). The methods used in each setting differ in the problems they have to solve.

Why semaglutide is analytically demanding

Semaglutide is a modified GLP-1 peptide with the molecular formula C187H291N45O59 and a molecular weight of roughly 4,114 Da.^[2] That size places it in a class between small molecules (most traditional drugs) and large proteins (monoclonal antibodies). Analysts cannot use the same toolbox for both ends of that spectrum, and the modifications Novo Nordisk made to extend semaglutide's half-life in the body, particularly the fatty-acid chain attached via a linker to make the molecule bind albumin in plasma, create additional analytical complexity. The drug needs methods that can separate it from closely related degradants, from endogenous GLP-1 in plasma samples, and from excipients in the pharmaceutical formulation.

Chromatographic methods: the workhorse category

The Kavibharathi review identifies reversed-phase HPLC as the most widely validated analytical approach for semaglutide in pharmaceutical formulations.^[1] Reversed-phase conditions separate the molecule by hydrophobicity on a non-polar stationary phase, typically a C18 or C8 column, using a gradient mobile phase. The method is well-suited to identity and assay testing in quality control, where the question is whether the product matches a reference standard at the expected potency.

A 2026 study in BMC Chemistry by Khalil, Hassanein, El-Yazbi, and Mahgoub took this a step further, developing and validating the first stability-indicating HPLC method for semaglutide and tirzepatide simultaneously.^[3] Stability-indicating methods are specifically designed to detect degradation products generated by heat, light, humidity, and oxidation. The Khalil team reported a detection limit for semaglutide of 16 ng/mL, a linearity range of 1 to 500 micrograms per millilitre with a correlation coefficient above 0.9999, and confirmed the method met ICH Q2(R1) validation criteria. They also applied green analytical chemistry assessments, indicating the method uses less hazardous solvent than earlier approaches.

LC-MS/MS for pharmacokinetic studies

When semaglutide moves from the pen injector into a patient's circulation, measuring plasma concentrations requires sensitivity several orders of magnitude beyond what HPLC assays of finished products need. A 2026 Bioanalysis paper by Tudan, Stickling, Northwick Darden, Devine, and Needham described development of a triple-quadrupole HPLC-MS/MS assay for semaglutide in human plasma.^[4] The method operates across a concentration range of 5 to 200 ng/mL, with accuracy of 92.7% to 109.4% and precision below 10.6%, and uses stable isotope-labelled internal standards and protein precipitation for sample preparation. The authors note the method is aligned with 2022 FDA M10 bioanalytical method validation guidance.

The choice of triple-quadrupole LC-MS/MS for plasma analysis reflects a practical constraint: semaglutide's fatty-acid modification creates substantial ion-suppression risk from matrix components in plasma, and the high selectivity of tandem mass spectrometry is needed to distinguish the intact drug from endogenous peptides and from co-eluting matrix constituents.

Spectroscopic and other approaches

Beyond chromatography, the Kavibharathi review covers UV-visible spectrophotometry, FTIR, and Raman spectroscopy as supplementary or screening tools.^[1] UV-Vis detection is often paired with HPLC as a detector (semaglutide absorbs at 214 to 220 nm) but is insufficiently selective when used alone for complex matrices. FTIR and Raman offer structural fingerprinting useful in counterfeit-detection applications, where regulators and quality teams need to identify whether a seized product contains the correct peptide at all. These spectroscopic methods are faster than chromatographic ones but are generally not used as the primary validation method for release testing.

Why this matters outside the laboratory

Analytical method development for prescription drugs is normally a technical subject that stays inside manufacturer quality-control departments. Semaglutide is unusual because concerns about the grey market and about the quality of compounded versions have made the analytical question relevant to a broader audience. The FDA's April 2026 clarification of its compounding policies confirmed that enforcement discretion for large-scale semaglutide compounding has ended, partly because branded supply has stabilised and partly because independently tested compounded products have shown variability in content and purity.^[5] The EMA's Ozempic EPAR and parallel MHRA communications have flagged counterfeit pens entering legitimate supply chains.

For readers considering the analytical literature from a patient or research perspective: what the Kavibharathi review documents is the validated toolkit that regulators and manufacturers use to confirm that a product is what it says it is. Chromatographic methods remain the standard because they can resolve the intact peptide from its degradants and from matrix interferences with documented accuracy, precision, and sensitivity. Spectroscopic screens are fast but not sufficient for release testing. Plasma LC-MS/MS is the standard for pharmacokinetic work because plasma matrices require both high sensitivity and high selectivity.

What this review does not resolve

The Kavibharathi paper is a review of published methods, not a head-to-head validation study. The authors document what has been published, assess the relative merits, and identify reversed-phase HPLC and LC-MS/MS as the most effective current approaches. They do not validate a single universal method or define a compendial standard. A compendial monograph for semaglutide, if one were to be adopted by a pharmacopoeia, would require additional collaborative study. The review serves as a guide for investigators setting up new analytical programmes, not as a regulatory specification.